

**Author Index**  
**Volume 74**  
**July–December, 2006**

- Abraham, B., 188  
 Abuabara, K., 394  
 Ahrendt, H.-J., 451  
 Ajayi, A., 194  
 Akin, A., 376  
 Akkuzu, G., 376  
 Aldrighi, J.M., 446  
 Ali, N., 125  
 Alibayeva, G., 318  
 Alizade, S.M., 483  
 Allen, R.H., 407  
 Ambardekar, S., 179  
 Anderson, F., 181  
 Anderson, F.D., 355  
 Andrade, R.P., 446  
 Andrist, L.C., 174  
 Archer, D., 179  
 Archer, D.F., 359, 439  
 Arias, R.D., 234  
 Arkutu, A., 194  
 Aronsson, A., 31  
 Arslin, A., 191  
 Ashraf, A., 382  
 Auerswald, C., 186  
  
 Badon, S., 194  
 Baga, R.I., 483  
 Bahamondes, L., 259  
 Baird, D., 3  
 Bajos, N., 195, 208, 476  
 Ballagh, S., 179  
 Ballagh, S.A., 133  
 Bankole, A., 188  
 Bapst, J.L., 414  
 Barbosa, I.C., 492  
 Barnes-Harper, K.T., 214  
 Barnhart, K., 182, 192  
 Bastianelli, C., 451  
 Bautista, C.T., 318  
 Bay, R.C., 313  
 Becker, B.M., 201  
  
 Bednarek, P., 178  
 Belfield, T., 280  
 Benedict, C., 180  
 Betstadt, S., 193  
 Bitzer, J., 451  
 Black, K.I., 309  
 Blanchard, K., 176  
 Blum, J., 191, 194  
 Blumenthal, P., 191  
 Blumenthal, P.D., 249, 272  
 Bock, B.C., 201  
 Borenstein, J., 249  
 Borges, L.E., 446  
 Borisute, H., 439  
 Borrero, S., 193  
 Bost, J., 193  
 Botto, A., 492  
 Bouyer, J., 118, 188  
 Brache, V., 133  
 Bracken, H., 179  
 Brenner, P., 354  
 Broyles, M., 189  
 Brucker, C., 234  
 Burke, A., 183  
 Burrows, M., 487  
 Bygdeman, M., 31  
  
 Cagiano, R., 220  
 Cahill, S., 36  
 Callahan, M., 133  
 Camargos, A.F., 446  
 Camus, A., 197  
 Candel, A., 328  
 Carbonell Esteve, J.L., 328  
 Carrera, J., 188  
 Carlson, N., 196  
 Carr, J.K., 318  
 Castleman, L., 36  
 Castleman, L.D., 272  
 Chavira, W., 313  
 Chen, P., 181  
  
 Cheng, L., 61  
 Chung-Park, M., 196  
 Clark, L.R., 214  
 Clark, M.A., 201  
 Clark, S., 195  
 Cohen-Landau, S., 194  
 Cohn, L., 195  
 Colwell, H.H., 303  
 Constantine, G.D., 439  
 Coonrod, D.V., 313  
 Cooper, E., 183  
 Copas, A.J., 224, 498  
 Costales, A., 178, 184  
 Coulhart, S., 157  
 Coutinho, E., 492  
 Coyaji, K., 179  
 Creinin, M., 133, 178, 179, 181, 182, 184, 186, 193, 458  
 Cremer, M., 176, 191  
 Crockett, S.A., 174  
 Croxatto, H., 181  
 Cushman, L., 180, 192  
 Cwiak, C., 186, 191  
  
 Dalton, V., 195  
 Damergis, J.A., 201  
 Danielsson, K.-G., 66  
 Daponte, A., 324  
 Darney, P., 104  
 Dauphinee, L.A., 334  
 Davey, A., 16  
 Davis, A., 197  
 Davis, S., 179, 187  
 Dela Cruz, M., 180  
 Deloughery, T., 191  
 Deutsch, M., 345  
 Dhanaraju, M.D., 148  
 Diaz Olavarrieta, C., 193  
 Diaz-Olavarrieta, C., 264  
 Diaz-Olavarrieta, C., 394  
 Dilbaz, B., 376

- Dimopoulos, K.D., 324  
 Diop, A., 191, 194  
 Doh, A.S., 118  
 dos Santos Fernandes, A.M., 259  
 Downing, D., 185  
 Doyle, L.L., 351  
 Dries-Daffner, I., 190  
 Dubois, R.W., 249  
  
 Earhart, K.C., 318  
 Edelman, A., 191  
 Edelman, A., 196  
 Edwards, S., 180, 192  
 Egger, K., 367  
 El-Mallah, S.Y., 297  
 Epstein, L., 186  
 Equils, O., 175  
 Erben, R.G., 367  
 Eren, B., 224  
 Erens, B., 498  
 Ermer, J.C., 414  
 Eroglu, K., 376  
 Espey, E., 184, 389  
  
 Falk, G., 471  
 Fang, A., 187  
 Fatuma, A.B., 400  
 Felsenberg, D., 367  
 Fendrick, A., 195  
 Fenton, K., 224, 498  
 Ferron, G.M., 414  
 Fiala, C., 66  
 Fichorova, R.N., 133  
 Finer, L., 186  
 Finer, L.B., 334  
 Fitzmaurice, G., 407  
 Fogg, K., 191  
 Fogle, R.H., 245  
 Fortner, K., 190  
 Foss, D., 414  
 Fosse, I., 190  
 Foster, A., 193  
 Foster, A.M., 264  
 Foster-Rosales, A., 180  
 Frederick, C., 196  
 Frezieres, R.G., 110  
 Friedman, A.J., 303  
 Frimpong, P., 194  
 Frohwirth, L.F., 334  
  
 Gainer, E., 118  
 Gallo, M.F., 36  
 Galper, C., 189  
 Gardner, J., 185  
 Gaydos, L., 188  
  
 Gazi, R., 382  
 Gee, E.M., 201  
 Gemzell-Danielsson, K., 31, 451  
 Gerds, C., 190  
 Ghosh, D., 419  
 Gilbert, F., 208  
 Gill, G., 184  
 Gilliam, M., 179, 187  
 Ginsburg, K.R., 214  
 Glasier, A.F., 287  
 Glik, A., 345  
 Gmach, R., 382  
 Godfrey, E., 189  
 Göhler, K., 239  
 Gold, M., 185, 189  
 Goldberg, A.B., 407  
 Goldfarb, I., 194  
 Gómez, M.A., 451  
 Goodman, S., 180  
 Goulard, H., 208  
 Granot, M., 345  
 Grimes, D.A., 174, 280  
 Grossman, D., 394  
 Grubb, G.S., 439  
 Guazelli, C., 446  
 Guidozzi, F., 324  
 Guo, A., 249  
 Gupta, R.C., 165  
 Guzik, D., 183  
  
 Haberal, A., 376  
 Halmesmaki, K., 182  
 Harper, C.C., 104  
 Harris, L., 195  
 Hart, K.W., 313  
 Hartard, M., 367  
 Harwood, B., 179, 181, 182, 184, 190  
 Harwood, B.J., 458  
 Hassan, M., 297  
 Hayes, J., 181  
 Hazarika, A., 426  
 Hearst, N., 196  
 Heartwell, S., 180, 192  
 Helmerhorst, F.M., 280  
 Hicks, S., 191  
 Hillier, S., 182  
 Hillier, S.L., 133  
 Ho, P.C., 11, 26  
 Hockert, P., 194  
 Hogue, C., 188  
 Holmes, W.C., 214  
 Holmquist, S., 187  
 Hubacher, D., 181  
 Hurskainen, R., 182  
 Hwang, A.C., 435  
  
 Hyman, A.G., 272  
  
 Ibrahim, S., 193  
 Isaia, C.F., 446  
 Ivey, S., 186  
  
 Jain, J.K., 234, 293  
 Jakobi, P., 345  
 James, E., 185  
 Jamshidi, R., 183  
 Janowitz, B., 382  
 Jayakumar, R., 148  
 Jenabi, E., 483  
 Jensen, J., 178, 184, 186, 196  
 Jensen, J.T., 439  
 Jick, H., 290, 354  
 Jick, S.S., 290, 354  
 Job-Spira, N., 208  
 Joffe, C., 1  
 Johnson, A., 183  
 Johnson, A.M., 224, 309, 498  
 Johnson, J.V., 439  
 Jones, R., 188  
 Jordan, B., 87, 199  
 Juliato, C.T., 259  
  
 Kalmuss, D., 180, 192  
 Karasek, D., 195  
 Karskov, B., 451  
 Karvois, D.L., 303  
 Katz, A.I., 176  
 Kaunitz, A.M., 90  
 Kaye, J.A., 354  
 Kayembe, P.K., 400  
 Kenfack, B., 118  
 Kim, L., 104  
 Kleinmond, C., 367  
 Kneip, C., 239  
 Korner, P., 178, 184  
 Kost, K., 188  
 Kottke, M., 191  
 Kramer, M., 188  
 Krishna, U., 179  
 Kritzer, J., 197  
 Krohn, M., 179  
 Kuehl, T.J., 100  
 Kulier, R., 280  
 Kumar, A., 194  
 Kumar, D., 407  
 Kumar, V., 165  
 Kunins, H., 185  
  
 Lai, J.-J., 133  
 Lakha, F., 287  
 Lal, J., 165

- Lalitkumar, P.G., 419  
 Lalor, M., 186  
 Landau, S., 190  
 Landau, S.C., 463  
 Lara, D., 394  
 Lawton, B., 353  
 Le, S., 185  
 Leal, P., 328  
 Lee, C., 389  
 Leeman, L., 184, 389  
 Leggat, M., 179  
 Leng, X., 141  
 Leonard, C.J., 313  
 Lifford, K.L., 407  
 Lillo, S., 181  
 Lindberg, L., 186  
 Lintu, H., 178  
 Liu, C.Y., 104  
 Liu, Z., 249  
 Llorente, M., 328  
 LoCoco, J.M., 303  
 Lohr, P., 181, 182  
 Lopes, A.C., 492  
 Lopes, R., 492  
 Lowenstein, L., 345  
 Lui, Y.-X., 157  
 Luppa, P., 367  
  
 Ma, G., 141  
 MacDonald, J., 352  
 Macdowall, W., 224, 498  
 Mactyszczuk, S., 157  
 Magnuson, A., 471  
 Mahnert, N., 192  
 Maia, H. Jr., 492  
 Maitra, N., 280  
 Mambu, T., 400  
 Mandelkar, A., 179  
 Mapatano, M.A., 400  
 Mari, J.M., 328  
 Marions, L., 21  
 Marques, M., 190  
 Martin, S., 193  
 Masch, R., 191  
 Mathias, S.D., 303  
 Mauck, C., 133  
 Mboudou, E., 118  
 McClung, M.R., 90  
 McGhee, B.T., 463  
 McGregor, J.A., 175  
 McNeil, M., 193  
 Meckstroth, K., 194  
 Méndez, J.F., 382  
 Mercer, C., 224, 498  
 Mercer, C.H., 309  
  
 Merchant, R.C., 201  
 Meyn, L., 178, 179  
 Michaelson, J., 189  
 Milan, F., 185  
 Miller, L., 185  
 Miller, P.D., 90  
 Miller, S., 196  
 Milsom, I., 451  
 Mitchell, E.M., 36  
 Mittal, S., 56  
 Mohsen, I.A., 297  
 Monastersky, N., 194  
 Moore, A.M., 334  
 Moreau, C., 188, 195, 208, 476  
 Mullen, P.D., 350  
 Muñoz, E., 328  
 Murphy, P.A., 245  
 Myers, E.R., 277  
  
 Najwa, A.R., 419  
 Nanchahal, K., 224, 498  
 Nasso, J., 183  
 Nelson, A., 178, 184, 194  
 Nguer, R., 382  
 Nguyen, D., 190  
 Nguyen, T., 184  
 Nilsson, K., 471  
 Nisand, I., 451  
 Noronha, C., 492  
 Nzewenga, G., 324  
  
 Oanh, K.T.H., 272  
 O'Brien, P., 280  
 Oeyen, L., 451  
 Ogburn, T., 184, 389  
 Okonofua, F., 194  
 Olenja, J., 382  
 Olubuyide, T., 185  
 on behalf of the participants of the  
     consensus meeting held at the  
     Bellagio Study and Conference  
     Center, 3  
 O'Neill, E., 186  
 Orczyk, G.P., 414  
 Östlund, I., 471  
 Özel, B., 293  
  
 Paavonen, J., 182  
 Pack, A., 197  
 Page, G., 451  
 Patel, A., 183, 187  
 Patel, D., 183, 187  
 Peixoto, F.C., 446  
 Penney, G., 45  
 Pera-Floyd, M., 180  
  
 Perez, M., 194  
 Peters, C., 487  
 Petracco, A., 446  
 Pillai, S., 187  
 Piotrowskin, H., 183, 187  
 Poindexter, A.N., 125  
 Posner, S., 125  
 Preskill, F., 195  
 Prezioso, A., 351  
 Pritchard, M.L., 303  
 Pruitt, S.L., 350  
  
 Qualls, C., 389  
  
 Raine, T., 186  
 Raine, T.R., 104  
 RajKannan, R., 148  
 Rakotovao, J., 191  
 Raote, V., 179  
 Ray, A., 234  
 Raymond, E., 179, 349  
 Reddy, S., 389  
 Reeves, M., 180, 181, 182, 184  
 Reeves, M.F., 458  
 Reyes, V., 181  
 Rice, V.M., 90  
 Robertson, P., 195  
 Rose, S., 353  
 Rosenberg, K., 196  
 Ross, D., 90, 234  
 Rouhana, A., 264  
 Rubin, S., 189  
 Russmann, S., 354  
  
 Sabatini, R., 220  
 Salvador, I., 328  
 Sambol, N.C., 104  
 Sammel, M., 182  
 Sampson, O., 196  
 Sanchez, J.L., 318  
 Sangi-Haghpeykar, H., 125  
 Sankey, H., 193  
 Santelli, J., 186  
 Sarma, H.N., 426  
 Saxena, S., 224, 498  
 Schaff, E., 42  
 Schaffner, K., 193, 264  
 Schollin, J., 471  
 Schreiber, C., 178, 182, 184, 458  
 Schwartz, J.L., 133  
 Schwarz, D.F., 214  
 Schwarz, E., 193  
 Selvaraj, D., 148  
 Sengupta, J., 419

- Seoudi, S., 297  
 Serrano, M., 328  
 Shaarawy, M., 297  
 Shand, C., 352  
 Shepherd, J., 353  
 Shields, W.C., 1, 199, 351, 435  
 Shittu, O., 194  
 Shotorbani, S., 185  
 Siler-Khodr, T.M., 157  
 Simões, J.A., 259  
 Singh, M.M., 165  
 Singh, R., 183  
 Singh, R.H., 249  
 Singh, S., 186, 188, 334  
 Sitruk-Ware, R., 48, 352  
 Smith, T., 186  
 Sobota, M., 185  
 Sobreira-Lima, B., 259  
 Sokal-Gutierrez, K., 186  
 Song, C., 141  
 Sparrow, M., 352  
 Spiekerman, A.M., 100  
 Stanczyk, F.Z., 245, 293  
 Stanwood, N., 183  
 Steinauer, J., 195  
 Stewart, F.H., 435  
 Stuart, G., 192  
 Sulak, P.J., 100  
 Sun, H., 141  
 Tamir, A., 345  
 Tang, O.S., 26  
 Tao, S.-X., 157  
 Tapias, M.P., 463  
 Taşkın, L., 376  
 Taylor, J., 194  
 Taylor-McGhee, B., 190, 194  
 Teperi, J., 182  
 Terlinden, R., 239  
 the Cocon Group, 208  
 Thuy, L.T., 272  
 Todd, C.S., 318  
 Treece, Y., 181  
 Trouton, K., 187  
 Trussell, J., 87, 188, 193, 195, 249, 264, 476  
 Tudela, A., 328  
 Uddin, M., 178, 184  
 Uragg, H., 239  
 Urdl, W., 451  
 Valero, F., 328  
 Vamsadhara, C., 148  
 Varela, L., 328  
 Vaughan, B., 188  
 Venkat, P., 191  
 Villarreal, M., 259  
 von Hertzen, H., 3  
 Vulis, M., 194  
 Vural, G., 376  
 Wagner, M., 178  
 Waheed, K., 189  
 Wallace, L., 180, 190  
 Walsh, T.L., 110  
 Ward, D., 357  
 Warkol, R., 185  
 Weber, A., 183, 187  
 Wei, P., 157  
 Weiner, D.H., 133  
 Weissenbacher, E.R., 367  
 Wellings, K., 224, 309, 498  
 Wesson, J., 382  
 Westhoff, C., 180, 181, 192  
 Westhoff, C.L., 245  
 White, T., 293  
 Wiebe, E., 187  
 Willis, S.A., 100  
 Winikoff, B., 176, 179, 191, 194  
 Wiseman, M., 367  
 Wynn, L., 193, 264  
 Yang, J., 141  
 Yazlle, M.E.H., 446  
 Yoon, A., 197  
 Young, V., 190  
 Yount, K., 188  
 Yu, F.-Q., 157  
 Zelger, O., 367  
 Zepeda, A., 181  
 Zieman, M., 180, 192  
 Zimmer, E.Z., 345  
 Zite, N., 179-181, 185, 190

**Subject Index**  
**Volume 74**  
**July–December, 2006**

- Abortifacients, pharmacy access in a Latin American city, 394
- Abortion,
  - in the United States, timing of steps and reasons for delays in obtaining of, 334
  - utilization, relation to HIV infection among female sex workers in Tashkent, Uzbekistan, 318
- Abstracts, ARHP 2006 meeting, 178
- Acceptability,
  - CS gel, 133
  - IUD checklist screening tool, provider views on, 382
  - medical abortion, review, 11
  - mifepristone and multiple misoprostol doses for abortion up to 10 weeks of gestation, review, 36
  - oral vs vaginal misoprostol regimens for medical abortion, 176
- Adolescents,
  - vs adults, pharmacokinetics of single-dose LNG, 104
  - women, perceptions on menstrual irregularity caused by hormonal contraception, 214
- Adults, vs adolescents, pharmacokinetics of single-dose LNG, 104
- Advance provision, vs information, impact on EC use by age and ethnicity, randomized trial, 110
- Age, EC use based on, impact of advance provision vs information, randomized trial, 110
- Amlodipine, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Amoxicillin, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Analgesia,
  - requirements, and pain, during medical abortion, review, 45
  - suppository, efficacy in postabortion pain reduction, 345
- Androgenicity, of progestin in OC pills, effects on maximal leg strength, 487
- Anesthesia, local, with or without lorazepam or intravenous sedation for pain in first-trimester surgical abortion, 407
- Anti-leukemia inhibitory factor monoclonal antibody, effects on blastocyst implantation (rhesus monkey), 419
- Antiandrogenic activity, of OC pills, effects of St. John's Wort on, 245
- ARHP (Association of Reproductive Health Professionals) Association of Reproductive Health Professionals (ARHP) editorial,
  - adding value to reproductive health research, 199
  - maximizing benefit of HPV vaccines, 277
  - mechanism of action of EC pills, 87
  - morality and the abortion provider, 1
  - reasons for reading editorials, 357
  - ten priorities for women's health, 435
- Association of Reproductive Health Professionals (ARHP) 2006 meeting, abstracts, 178
- Atenolol, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Attitudes,
  - on contraception, between Hispanic and non-Hispanic whites, 125
  - of women
    - and providers toward menstrual suppression with extended use OC, 174
    - toward pharmacy access to hormonal contraception, 463
    - urban Hispanic, on natural family planning, 313
- Biocompatibility, of injectable PLG microspheres containing LNG + EE, 148
- Biodegradable contraceptive implant, long-acting LNG-releasing, preclinical studies (rats and dogs), 141
- Biodegradation, of injectable PLG microspheres containing LNG + EE, 148
- Blastocyst implantation, effects of anti-leukemia inhibitory factor monoclonal antibody (rhesus monkey), 419
- Bleeding pattern,
  - after LNG EC, 118
  - in subcutaneous injection of DMPA, 234
  - after use of LNG EC pills, 349

- BMD (Bone mineral density)  
Bone geometry, effects of desogestrel vs LNG, 367  
Bone mass, effects of desogestrel vs LNG, 367  
Bone mineral density (BMD),  
  effects of desogestrel vs LNG, 367  
  effects of long-term DMPA use, 297  
  in users of two kinds of once-a-month combined injectable contraceptives, 259  
  in women aged 25-35 years, effect of DMPA, 90  
Bone remodeling, effects of long-term DMPA use, 297  
Breastfeeding women, in New Mexico, conformity of OC prescribing with current guidelines, 389  
Buccal administration, misoprostol, and manual vacuum aspiration, for second-trimester abortion in Vietnam, 272
- C-reactive protein, effects of OC vs transdermal patch, 293  
Cefixime, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165  
Cellulose sulfate (CS) gel, safety and acceptability, 133  
Centchroman, effects of coadministered drugs on postcoital contraceptive efficacy and pharmacokinetic profile of (rats), 165  
Cerebral venous sinus thrombosis, in users of four hormonal contraceptives, 290  
Cervical priming, in first-trimester abortion, vaginal vs sublingual misoprostol for, 328  
Cesarean section (CS), previous single, vaginal misoprostol for TOP in women with, 324  
China, medical abortion in early pregnancy, review, 61  
Chlormadinone acetate (CMA), pharmacokinetics after single and multiple oral doses of CMA + EE, 239  
Ciprofloxacin, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165  
*Clostridium sordelii*, causing mifepristone-induced septic shock, 174  
CMA (Chlormadinone acetate)  
COC (Combine oral contraceptive)  
Cochrane Fertility Regulation Group, best evidence on family planning, 280  
Combined oral contraceptive (COC), vs vaginal ring, cycle control, tolerability and sexual satisfaction among users, 220  
Complications, of IUD insertion in immediate postpartum/early postpartum period, 376  
Continuation rate,  
  Implanon® in the UK, 287  
  TCu380A IUD in Tabriz, Iran, 483  
Contraception,  
  international perspective, 351  
  after medical abortion, review, 56  
  Contraceptive activity, of GnRH II analog (rhesus monkeys), 157  
  Contraceptive efficacy, postcoital, of Centchroman, effects of coadministered drugs on (rats), 165  
  Contraceptive failure, and determinants of EC use, 208  
  Contraceptive implants,  
    biodegradable long-acting LNG-releasing, preclinical studies (rats and dogs), 141  
    Uniplant, effects on endometrial morphology and ovarian function, 492  
  Contraceptive patch, vs OC, cerebral venous sinus thrombosis in users of, 290  
  Contraceptive technology, improvement of, 350  
  Contraceptive use,  
    among Hispanic vs non-Hispanic whites, 125  
    EC, and contraceptive failures, 208  
    EC pills, determinants and circumstances of, in the context of direct pharmacy access in France, 476  
    and knowledge, among female ED patients, 201  
    modern, in Kinshasa, Democratic Republic of Congo, prevalence and determinants, 400  
    relation to HIV infection among female sex workers in Tashkent, Uzbekistan, 318  
    and sexual behavior, among women, ethnic variations in, 224  
  Corticosteroid-binding globulin, effects of OC vs transdermal patch, 293  
  Cost-effectiveness, of OC vs LNG-releasing IUS vs surgery for DUB, 249  
  CS (Cellulose sulfate)  
  Death, risk in mifepristone medical abortion, 174  
  Democratic Republic of Congo, prevalence and determinants of modern contraceptive use in Kinshasa, 400  
  Depot medroxyprogesterone acetate (DMPA),  
    bleeding patterns in subcutaneous injection of, 234  
    effect on BMD in women aged 25-35 years, 90  
    long-term use, effects on BMD and bone remodeling, 297  
  Desogestrel,  
    vs LNG, skeletal effects, 367  
    OC, vs contraceptive patch, cerebral venous sinus thrombosis in users of, 290  
  Dilation and evacuation, using manual vacuum aspiration and buccal misoprostol for second-trimester abortion in Vietnam, 272  
  Discontinuation, reasons for, of TCu380A IUD in Tabriz, Iran, 483  
  DMPA (Depot medroxyprogesterone acetate)  
  Drospirenone + EE,  
    efficacy and safety in women with premenstrual disorders, 446  
    oral, vs NuvaRing, efficacy, safety and tolerability, 451  
  DUB (Dysfunctional uterine bleeding)  
  Dysfunctional uterine bleeding (DUB), cost-effectiveness of surgery vs LNG-releasing IUS vs OC, 249



- EC (Emergency contraception)
- ED (Emergency department)
- EE (Ethinyl estradiol)
- Efficacy,  
  continuous LNG + EE, 439  
  drospirenone + EE in women with premenstrual disorders, 446  
  IUD insertion in immediate postplacental/early postpartum period, 376  
  mifepristone + misoprostol for medical abortion, review, 21  
  mifepristone and multiple misoprostol doses for abortion up to 10 weeks of gestation, review, 36  
  NuvaRing vs oral EE + drospirenone, 451  
  oral vs vaginal misoprostol regimens for medical abortion, 176  
  Seasonique™, 355  
  suppository analgesia for postabortion pain reduction, 345
- Emergency contraception (EC),  
  advance provision vs information, impact on use by age and ethnicity, randomized trial, 110  
  hormonal, sociodemographic and sexual health profile of users, 309  
  LNG, bleeding pattern after, 118  
  use of, and contraceptive failures, 208
- Emergency contraception (EC) pills,  
  bleeding patterns after use of LNG, 349  
  determinants and circumstances of contraceptive use in the context of direct pharmacy access in France, 476  
  mechanism of action, ARHP editorial, 87
- Emergency department (ED), contraceptive use and knowledge among female patients, 201
- Endometrial hyperplasia, effects of *Polygonum hydropiper* root extract (rats), 426
- Endometrial morphology, effects of Uniplant, 492
- Estradiol, reduced ovarian production due to shortened hormone-free interval of OC regimens, 100
- Estrogen-sensitive hepatic proteins, effects of OC vs transdermal patch, 293
- Ethinyl estradiol (EE),  
  continuous low-dose, safety and efficacy of extended-regimen OC utilizing, 355  
  pharmacokinetics after single and multiple oral doses of CMA + EE, 239
- Ethinyl estradiol (EE) + drospirenone,  
  efficacy and safety in women with premenstrual disorders, 446  
  oral, vs NuvaRing, efficacy, safety and tolerability, 451
- Ethinyl estradiol (EE) + LNG,  
  in injectable PLG microspheres, biodegradation and biocompatibility of, 148  
  safety and efficacy of continuous regimen, 439
- Ethinyl estradiol (EE) + norgestimate, OC vs transdermal patch, risk of nonfatal VTE in women using, 354
- Ethnic groups, variations in sexual behavior and contraceptive use among women, 224
- Ethnicity, EC use based on, impact of advance provision vs information, randomized trial, 110
- Extended cycle OC, utilizing continuous low-dose EE, safety and efficacy, 355
- Family planning,  
  best evidence on, Cochrane Fertility Regulation Group, 280  
  natural, attitudes among urban Hispanic women, survey of, 313
- Females. *see* Women
- Follicular recruitment, effects of *Polygonum hydropiper* root extract (rats), 426
- France, determinants and circumstances of EC pill use in the context of direct pharmacy access, 476
- Gemeprost, shortened time interval after mifepristone for medical abortion, review, 42
- Glibenclamide, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- GnRH II analog (Gonadotropin-releasing hormone (GNRH) II analog)
- Gonadotropin-releasing hormone (GnRH) II analog, contraceptive activity of (rhesus monkeys), 157
- Gonadotropins, reduced pituitary secretion due to shortened hormone-free interval of OC regimens, 100
- Healthy education, usage patterns of a multilingual web site on TOP information, 264
- Hepatic proteins, estrogen-sensitive, effects of OC vs transdermal patch, 293
- Hispanics,  
  vs non-Hispanic whites, contraceptive knowledge, attitude and use, 125  
  urban women, survey of attitudes on natural family planning, 313
- HIV infection (Human immunodeficiency virus (HIV) infection)
- Hormonal contraception,  
  4 types, cerebral venous sinus thrombosis in users of, 290  
  adolescent women's perceptions on menstrual irregularity caused by, 214  
  emergency, sociodemographic and sexual health profile of users, 309  
  long-term use of DMPA, effects on BMD and bone remodeling, 297  
  survey on women's attitudes toward and interest in pharmacy access to, 463
- Hormone-free interval of OC use, shortened, causes greater inhibition of the pituitary-ovarian axis, 100
- HPV vaccines, maximizing benefit of, ARHP editorial, 277

- Human immunodeficiency virus (HIV) infection, relation to contraception and abortion utilization among female sex workers in Tashkent, Uzbekistan, 318
- Hyperplasia, endometrial, effects of *Polygonum hydropiper* root extract (rats), 426
- Implanon<sup>®</sup>, continuation rate in the UK, 287
- Induced abortion, using mifepristone, atypical presentation of PID after, 352
- Inhibin-B, reduced ovarian production due to shortened hormone-free interval of OC regimens, 100
- Injectable contraceptive, once-a-month combined, BMD in users of, 259  
PLG microspheres containing LNG + EE, biodegradation and biocompatibility of, 148
- Interest, of women in pharmacy access to hormonal contraception, 463
- Internet, usage patterns of a multilingual web site on TOP information, 264
- Intrauterine device (IUD), checklist screening tool, provider views on acceptability of, 382  
efficacy and complications of insertion in immediate postplacental/early postpartum period, 376  
TCu380A, continuation rates and reasons for discontinuation in Tabriz, Iran, 483
- Intrauterine system (IUS), LNG-releasing, vs OC, vs surgery, for DUB, cost-effectiveness of, 249
- Iran, continuation rates and reasons for discontinuation of TCu380A IUD in Tabriz, 483
- IUD (Intrauterine device)
- IUS (Intrauterine system)
- Kinshasa, Democratic Republic of Congo, prevalence and determinants of modern contraceptive use, 400
- Knowledge, on contraception, among female ED patients, 201  
between Hispanic and non-Hispanic whites, 125
- Latin America, pharmacy access to abortifacients in a city in, 394
- Leg strength, maximal, effects of androgenicity of progestin in OC pills, 487
- Leukemia inhibitory factor, monoclonal antibodies to, effects on blastocyst implantation (rhesus monkey), 419
- Levonorgestrel (LNG), vs desogestrel, skeletal effects, 367  
EC, bleeding pattern after, 118  
EC pills, bleeding patterns after use of, 349  
OC, vs contraceptive patch, cerebral venous sinus thrombosis in users of, 290  
single-dose, pharmacokinetics in adolescents vs adults, 104
- Levonorgestrel (LNG) + EE, in injectable PLG microspheres, biodegradation and biocompatibility of, 148  
safety and efficacy of continuous regimen, 439
- Levonorgestrel-releasing implant, biodegradable long-acting, preclinical studies (rats and dogs), 141
- Levonorgestrel-releasing IUS, vs OC, vs surgery, for DUB, cost-effectiveness of, 249
- LNG (Levonorgestrel)
- Long-acting contraceptive implant, biodegradable LNG-releasing, preclinical studies (rats and dogs), 141
- Lorazepam, or intravenous sedation, with or without local anesthesia, for pain in first-trimester surgical abortion, 407
- Manual vacuum aspiration, and buccal misoprostol, for second-trimester abortion in Vietnam, 272
- Medical abortion, contraception after, review, 56  
in early first-trimester, pharmacokinetics and regimens of misoprostol, review, 26  
in early pregnancy, in China, review, 61  
efficacy of mifepristone + misoprostol, review, 21  
efficacy of oral vs vaginal misoprostol regimens, 176  
first-trimester, vaginal vs sublingual misoprostol for cervical priming in, 328  
frequently asked questions about, review, 3  
mifepristone + prostaglandin, review, 66  
mifepristone use and risk of death, 174  
pain and analgesia requirements during, review, 45  
provider, and morality, ARHP editorial, 1  
second-trimester, manual vacuum aspiration and buccal misoprostol in Vietnam, 272  
shortened time interval of prostaglandin after mifepristone for, review, 42  
up to 10 weeks of gestation, mifepristone and multiple misoprostol doses for, review, 36  
using mifepristone, atypical presentation of PID after, 352  
women's perceptions on, review, 11
- Menstrual cycle, among users of COC vs vaginal ring, 220  
irregularity caused by hormonal contraception, adolescent women's perceptions, 214  
after LNG EC, 118  
suppression of, in extended use OC, women's and providers' attitude toward, 174  
symptoms in continuous use OC, review, 359  
after use of LNG EC pills, 349
- Metformin, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Metronidazole, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165



- Mifepristone,  
atypical presentation of PID after induced abortion using,  
352  
in medical abortion, risk of death, 174  
resulting in septic shock, due to *Clostridium sordelii*, 174  
shortened time interval of prostaglandin after, for medical  
abortion, review, 42
- Mifepristone + misoprostol,  
effects of various routes of misoprostol on uterine  
contractility, review, 31  
efficacy in medical abortion, review, 21  
multiple misoprostol doses, for abortion up to 10 weeks  
of gestation, review, 36  
for treatment of early pregnancy failure, 458
- Mifepristone + prostaglandin,  
in medical abortion, review, 66  
for TOP, contraindications and rationale, review, 16
- Misoprostol,  
buccal, and manual vacuum aspiration, for second-  
trimester abortion in Vietnam, 272  
in early first-trimester medical abortion, pharmacokinetics  
and regimens, review, 26  
for medical abortion, efficacy of oral vs vaginal regimens,  
176  
pharmacy access in a Latin American city, 394  
shortened time interval after mifepristone for medical  
abortion, review, 42  
sublingual vs vaginal, for cervical priming in first-  
trimester abortion, 328  
vaginal, for TOP in women with previous single CS, 324
- Misoprostol + mifepristone,  
effects of various routes of misoprostol on uterine  
contractility, review, 31  
efficacy in medical abortion, review, 21  
multiple misoprostol doses, for abortion up to 10 weeks  
of gestation, review, 36  
for treatment of early pregnancy failure, 458
- Monoclonal antibodies, to leukemia inhibitory factor,  
effects on blastocyst implantation (rhesus monkey),  
419
- Morality, and the abortion provider, ARHP editorial, 1
- Mortality, risk in mifepristone medical abortion, 174
- Multilingual web site, on TOP information, usage patterns  
of, 264
- Natural family planning, attitudes among urban Hispanic  
women, survey of, 313
- New Mexico, conformity of current guidelines with OC  
prescribing in breastfeeding women, 389
- Norgestimate, OC, vs contraceptive patch, cerebral venous  
sinus thrombosis in users of, 290
- Norgestimate + EE, OC vs transdermal patch, risk of  
nonfatal VTE in women using, 354
- NuvaRing, vs oral EE + drospirenone, efficacy, safety and  
tolerability, 451
- OC (Oral contraceptive)
- Oral administration,  
misoprostol  
in early first-trimester medical abortion,  
pharmacokinetics of, review, 26  
with mifepristone, effects on uterine contractility,  
review, 31  
vs vaginal administration, of misoprostol  
efficacy in medical abortion, 176
- Oral contraceptive (OC),  
for breastfeeding women in New Mexico, conformity of  
prescribing practices with current guidelines, 389  
combined, vs vaginal ring, cycle control, tolerability and  
sexual satisfaction among users, 220  
continuous use, menstrual-cycle-related symptoms,  
review, 359  
vs contraceptive patch, cerebral venous sinus thrombosis  
in users of, 290  
desogestrel vs LNG, skeletal effects, 367  
EE + drospirenone, vs NuvaRing, efficacy, safety and  
tolerability, 451  
extended-use  
utilizing continuous low-dose EE, safety and efficacy,  
355  
women's and providers' attitude toward menstrual  
suppression with, 174  
vs LNG-releasing IUS, vs surgery, for DUB, cost-  
effectiveness of, 249  
shortened hormone-free interval causes greater inhibition  
of the pituitary-ovarian axis, 100  
vs transdermal patch  
containing norgestimate + EE, risk of nonfatal VTE in  
women using, 354  
effects on estrogen-sensitive hepatic proteins, 293
- Oral contraceptive (OC) pills,  
effects of St. John's Wort on antiandrogenic properties of,  
245  
progestin in, effects of its androgenicity on maximal leg  
strength, 487
- ORTHO Birth Control Satisfaction Assessment Tool,  
sensitivity to change and predictors of satisfaction, 303
- Ovarian function,  
effects of Uniplant, 492  
reduced estradiol and inhibin-B production due to shortened  
hormone-free interval of OC regimens, 100
- Pain,  
and analgesia requirements, during medical abortion,  
review, 45  
in first-trimester surgical abortion, effects of local  
anesthesia with or without lorazepam or intravenous  
sedation for, 407  
after TOP, efficacy of suppository analgesia for, 345
- Pelvic inflammatory disease (PID), atypical presentation  
after mifepristone-induced medical abortion, 352

- Pharmacokinetics,  
 of Centchroman, effects of coadministered drugs on (rats), 165  
 of CMA and EE after single and multiple oral doses of CMA + EE, 239  
 of misoprostol in early first-trimester medical abortion, review, 26  
 of single-dose LNG in adolescents vs adults, 104  
 of tanaproget in healthy women, 414
- Pharmacy access,  
 to abortifacients in a Latin American city, 394  
 direct, in France, determinants and circumstances of EC pill use in the context of, 476  
 to hormonal contraception, survey on women's attitudes toward and interest in, 463
- Pioglitazone, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Pituitary gland, reduced gonadotropin secretion due to shortened hormone-free interval of OC regimens, 100
- PLG microspheres (Poly (lactide-co-glycolide) (PLG) microspheres)
- Pluronic F68/poly  $\epsilon$ -caprolactone, as long-acting LNG-releasing implant, preclinical studies (rats and dogs), 141
- Poly  $\epsilon$ -caprolactone/pluronic F68, as long-acting LNG-releasing implant, preclinical studies (rats and dogs), 141
- Poly (lactide-co-glycolide) (PLG) microspheres, injectable, containing LNG + EE, biodegradation and biocompatibility of, 148
- Polygonum hydropiper*, root extract, effects on follicular recruitment and endometrial hyperplasia (rats), 426
- Post-abortion care, frequently asked questions about, review, 3
- Postpartum period, early, efficacy and complications of IUD insertion, 376
- Pre-abortion care, frequently asked questions about, review, 3
- Pregnancy, early,  
 experiences of medical abortion in China, review, 61  
 failure of, misoprostol + mifepristone for treatment of, 458
- Premenstrual disorders, efficacy and safety of EE + drospirenone in women, 446
- Progestin, in OC pills, effects of its androgenicity on maximal leg strength, 487
- Prostaglandin, shortened time interval after mifepristone for medical abortion, review, 42
- Prostaglandin + mifepristone,  
 in medical abortion, review, 66  
 for TOP, contraindications and rationale, review, 16
- Randomized controlled trials,  
 impact of advance provision vs information EC use by age and ethnicity, 110  
 safety and acceptability of CS gel, 133  
 skeletal effects of desogestrel vs LNG, 367  
 sublingual vs vaginal misoprostol for cervical priming in first-trimester abortion, 328
- Reproductive health research, adding value to, ARHP editorial, 199
- Research, in reproductive health, adding value to, ARHP editorial, 199
- Risk, of death in mifepristone medical abortion, 174
- Root extract, of *Polygonum hydropiper*, effects on follicular recruitment and endometrial hyperplasia (rats), 426
- Safety,  
 continuous LNG + EE, 439  
 of CS gel, 133  
 drospirenone + EE in women with premenstrual disorders, 446  
 mifepristone and multiple misoprostol doses for abortion up to 10 weeks of gestation, review, 36  
 NuvaRing vs oral EE + drospirenone, 451  
 Seasonique™, 355  
 of tanaproget in healthy women, 414
- Satisfaction, ORTHO Birth Control Satisfaction Assessment Tool, 303
- Seasonique™, safety and efficacy, 355
- Sedation, intravenous, or lorazepam with or without local anesthesia, for pain in first-trimester surgical abortion, 407
- Septic shock, mifepristone-induced, due to *Clostridium sordellii*, 174
- Sex-hormone-binding globulin, effects of OC vs transdermal patch, 293
- Sex workers, female, in Tashkent, Uzbekistan, relation of contraception and abortion utilization to HIV infection, 318
- Sexual behavior,  
 and contraceptive use, among women, ethnic variations in, 224  
 of hormonal EC users, 309
- Sexual satisfaction, among users of COC vs vaginal ring, 220
- Side effects, vaginal ring vs COC, 220
- Skeletal effects, of desogestrel vs LNG, 367
- St. John's Wort, effects on antiandrogenic properties of OC pills, 245
- Subcutaneous administration, of DMPA, bleeding patterns in, 234
- Sublingual administration,  
 misoprostol  
 in early first-trimester medical abortion,  
 pharmacokinetics of, review, 26  
 with mifepristone, effects on uterine contractility, review, 31

- Sublingual administration, (*continued*)  
 vs vaginal administration, of misoprostol for cervical priming in first-trimester abortion, 328
- Suppository analgesia, efficacy in postabortion pain reduction, 345
- Surgery, vs LNG-releasing IUS, vs OC, for DUB, cost-effectiveness of, 249
- Surgical abortion, first-trimester, effects of local anesthesia with or without lorazepam or intravenous sedation for pain in, 407
- Survey,  
 of attitudes on natural family planning among urban Hispanic women, 313  
 conformity of current guidelines with OC prescribing in breastfeeding women in New Mexico, 389  
 women's attitudes toward and interest in pharmacy access to hormonal contraception, 463
- Systematic review, Cochrane Fertility Regulation Group, best evidence on family planning, 280
- Tabriz, Iran, continuation rates and reasons for discontinuation of TCu380A IUD, 483
- Tanaproget, pharmacokinetics and safety in healthy women, 414
- Tashkent, Uzbekistan, relation of contraception and abortion utilization to HIV infection among female sex workers in, 318
- TCu380A IUD, continuation rates and reasons for discontinuation in Tabriz, Iran, 483
- Technology, contraceptive, improvement of, 350
- Teenagers, high-risk for unintended pregnancies, 471
- Termination of pregnancy (TOP),  
 contraception after, review, 56  
 contraindications and rationale of mifepristone + prostaglandin, review, 16  
 efficacy of oral vs vaginal misoprostol regimens, 176  
 efficacy of suppository analgesia for pain after, 345  
 usage patterns of a multilingual web site on, 264  
 in women with previous single CS, vaginal misoprostol for, 324
- Theophylline, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Thrombosis, cerebral venous sinus, in users of four hormonal contraceptives, 290
- Thyroxine-binding globulin, effects of OC vs transdermal patch, 293
- Time interval, shortened, of prostaglandin after mifepristone for medical abortion, review, 42
- Tolerability,  
 NuvaRing vs oral EE + drospirenone, 451  
 oral vs vaginal misoprostol regimens for medical abortion, 176
- TOP (termination of pregnancy)
- Transdermal patch, vs OC,  
 containing norgestimate + EE, risk of nonfatal VTE in women using, 354  
 effects on estrogen-sensitive hepatic proteins, 293
- Unintended pregnancy, high-risk in teenagers, 471
- Uniplant, effects on endometrial morphology and ovarian function, 492
- United Kingdom, continuation rate of Implanon®, 287
- United States, timing of steps and reasons for delays in obtaining abortion, 334
- Urban population, Hispanic women, survey of attitudes on natural family planning, 313
- Uterine bleeding, dysfunctional, cost-effectiveness of surgery vs LNG-releasing IUS vs OC, 249
- Uterine contractility, after mifepristone and various routes of misoprostol, review, 31
- Uzbekistan, relation of contraception and abortion utilization to HIV infection among female sex workers in Tashkent, 318
- Vaccines, for HPV, maximizing benefit of, ARHP editorial, 277
- Vaginal administration,  
 misoprostol  
 in early first-trimester medical abortion,  
 pharmacokinetics of, review, 26  
 with mifepristone, effects on uterine contractility, review, 31  
 for TOP in women with previous single CS, 324  
 vs oral administration, of misoprostol  
 efficacy in medical abortion, 176  
 vs sublingual administration, of misoprostol for cervical priming in first-trimester abortion, 328
- Vaginal ring, vs COC, cycle control, side effects and sexual satisfaction among users, 220
- Venous sinus thrombosis, cerebral, in users of four hormonal contraceptives, 290
- Venous thromboembolism (VTE), nonfatal,  
 risk in women using transdermal patch vs OC containing norgestimate + EE, 354
- Vietnam, buccal misoprostol and manual vacuum aspiration for second-trimester abortion in, 272
- VTE (Venous thromboembolism)
- Website, multilingual, on TOP information, usage patterns of, 264
- Women,  
 adolescent, perceptions on menstrual irregularity caused by hormonal contraception, 214  
 aged 25-35 years, effect of DMPA on BMD, 90  
 attitudes toward and interest in pharmacy access to hormonal contraception 463

Women, (*continued*)

- breastfeeding, in New Mexico, conformity of OC prescribing with current guidelines, 389
- contraceptive use and knowledge among ED patients, 201
- ethnic variations in contraceptive use and sexual behavior, 224
- healthy, pharmacokinetics and safety of tanaproget, 414
- nonfatal VTE risk in users of transdermal patch vs OC containing norgestimate + EE, 354

Women, (*continued*)

- perceptions on medical abortion, review, 11
- and providers, attitudes toward menstrual suppression, with extended use of OC, 174
- sex workers in Tashkent, Uzbekistan, relation of contraception and abortion utilization to HIV infection, 318
- urban Hispanic, survey of attitudes on natural family planning, 313
- Women's health, ten priorities, ARHP editorial, 435

